Sun Pharma Advanced Research Company Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹237.3
- Today's High:
- ₹255.15
- Open Price:
- ₹251.55
- 52W Low:
- ₹160.5
- 52W High:
- ₹265.75
- Prev. Close:
- ₹253.5
- Volume:
- 119052
Company Statistics
- Market Cap.:
- ₹74.32 billion
- Book Value:
- 15.801
- Revenue TTM:
- ₹2.34 billion
- Operating Margin TTM:
- -105.87%
- Gross Profit TTM:
- ₹2.10 billion
- Profit Margin:
- -100.56%
- Return on Assets TTM:
- -25.18%
- Return on Equity TTM:
- -81.83%
Company Profile
Sun Pharma Advanced Research Company Limited had its IPO on under the ticker symbol SPARC.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Sun Pharma Advanced Research Company Limited has a staff strength of 407 employees.
Stock update
Shares of Sun Pharma Advanced Research Company Limited opened at ₹251.55 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹237.3 - ₹255.15, and closed at ₹239.05.
This is a -5.7% slip from the previous day's closing price.
A total volume of 119,052 shares were traded at the close of the day’s session.
In the last one week, shares of Sun Pharma Advanced Research Company Limited have slipped by -4.15%.
Sun Pharma Advanced Research Company Limited's Key Ratios
Sun Pharma Advanced Research Company Limited has a market cap of ₹74.32 billion, indicating a price to book ratio of 33.5601 and a price to sales ratio of 42.7934.
In the last 12-months Sun Pharma Advanced Research Company Limited’s revenue was ₹2.34 billion with a gross profit of ₹2.10 billion and an EBITDA of ₹-2391376128. The EBITDA ratio measures Sun Pharma Advanced Research Company Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sun Pharma Advanced Research Company Limited’s operating margin was -105.87% while its return on assets stood at -25.18% with a return of equity of -81.83%.
In Q2, Sun Pharma Advanced Research Company Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 15.8%.
Sun Pharma Advanced Research Company Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-7.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sun Pharma Advanced Research Company Limited’s profitability.
Sun Pharma Advanced Research Company Limited stock is trading at a EV to sales ratio of 45.2056 and a EV to EBITDA ratio of -30.5907. Its price to sales ratio in the trailing 12-months stood at 42.7934.
Sun Pharma Advanced Research Company Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹8.30 billion
- Total Liabilities
- ₹1.79 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Sun Pharma Advanced Research Company Limited ended 2024 with ₹8.30 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹8.30 billion while shareholder equity stood at ₹5.13 billion.
Sun Pharma Advanced Research Company Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹1.79 billion in other current liabilities, in common stock, ₹-15918134000.00 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹5.80 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Sun Pharma Advanced Research Company Limited’s total current assets stands at ₹4.55 billion while long-term investments were ₹0 and short-term investments were ₹4.06 billion. Its net receivables were ₹327.10 million compared to accounts payable of ₹1.48 billion and inventory worth ₹0.
In 2024, Sun Pharma Advanced Research Company Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Sun Pharma Advanced Research Company Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹239.05
- 52-Week High
- ₹265.75
- 52-Week Low
- ₹160.5
- Analyst Target Price
- ₹
Sun Pharma Advanced Research Company Limited stock is currently trading at ₹239.05 per share. It touched a 52-week high of ₹265.75 and a 52-week low of ₹265.75. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹232.21 and 200-day moving average was ₹207.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7445.2% of the company’s stock are held by insiders while 157.6% are held by institutions.
Frequently Asked Questions About Sun Pharma Advanced Research Company Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson’s disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.